登录    
  
首页 > 期刊论文 > 论文摘要
NK细胞在肿瘤免疫治疗中的研究进展展
         
Progress in natural killer cells for tumor immunotherapy

摘    要
自从自然杀伤(natural killer,NK)细胞被发现距今已有40多年的时间,但随着近年来肿瘤免疫疗法取得巨大进展,NK细胞在肿瘤免疫治疗方面的潜力又引起了极大的关注。NK细胞是一种具有强力溶解细胞能力的先天性淋巴样细胞(innate lymphoid cells,ILC),具有调节免疫、抵御肿瘤和抗感染等作用。本文就NK细胞与肿瘤的相互关系以及在肿瘤免疫治疗中靶向NK细胞治疗的最新研究进展作一综述。
标    签 肿瘤   免疫治疗   自然杀伤T细胞   Neoplasms   Immunotherapy   Natural killer T-cells  
 
Abstract
Natural killer (NK) cells were discovered more than 40 years ago. With the great progress in tumor immunotherapy in recent years, the potential of NK cells has attracted great attention. NK cells are a kind of innate lymphoid cells endowed with potent cytolytic function, so they play an important role in regulating immunity and defending against microbial infection and tumors. In this paper, the relationship between NK cells and tumor as well as the new therapeutic approaches targeting NK cells in tumor immunotherapy is reviewed.

中图分类号 R730.51   DOI 10.3781/j.issn.1000-7431.2017.55.211

 
  购买该论文  中国光学期刊网论文下载说明
      


所属栏目 综述

基金项目 国家自然科学基金资助项目(编号:81403260,81573859);中国博士后科学基金资助项目(编号:2014M551639);江苏省自然科学基金资助项目(编号:1401138);2013年江苏高校优秀科技创新团队计划资助项目[编号:苏教科(2013)10号文];江苏高校品牌专业建设工程资助项目(编号:PPZY2015A070);江苏省中药优势学科资助项目[编号:苏政办发(2014)37号文];江苏省2015年度普通高校研究生科研创新计划资助项目(编号:KYZZ15_0271)

收稿日期 2016/3/23

修改稿日期 2016/8/29

网络出版日期

作者单位点击查看


引用该论文: CHEN Lichuan,WANG Siliang,YU Suyun,JIA Qi,ZHU Pingting,CHEN Wenxing,WANG Aiyun,LU Yin. Progress in natural killer cells for tumor immunotherapy[J]. Tumor, 2017, 37(1): 101~106
陈力川,汪思亮,余苏云,贾琦,祝娉婷,陈文星,王爱云,陆茵. NK细胞在肿瘤免疫治疗中的研究进展展[J]. 肿瘤, 2017, 37(1): 101~106


论文评价
共有人对该论文发表了看法,其中:
人认为该论文很差
人认为该论文较差
人认为该论文一般
人认为该论文较好
人认为该论文很好
分享论文
分享到新浪微博 分享到腾讯微博 分享到人人网 分享到 Google Reader 分享到百度搜藏分享到Twitter

参考文献
【1】Artis D, Spits H. The biology of innate lymphoid cells[J]. Nature, 2015, 517(7534):293-301.
 
【2】Stojanovic A, Cerwenka A. Natural killer cells and solid tumors[J]. J Innate Immun, 2011, 3(4):355-364.
 
【3】Mentlik James A, Cohen AD, Campbell KS. Combination immune therapies to enhance anti-tumor responses by NK cells[J]. Front Immunol, 2013, 4:481.
 
【4】Peruzzi G, Masilamani M, Borrego F, et al. Endocytosis as a mechanism of regulating natural killer cell function:unique endocytic and trafficking pathway for CD94/NKG2A[J]. Immunol Res, 2009, 43(1-3):210-222.
 
【5】Ljunggren HG, Karre K. In search of the ‘missing self’:MHC molecules and NK cell recognition[J]. Immunol Today, 1990, 11(7):237-244.
 
【6】Roder JC, Haliotis T, Klein M, et al. A new immunodeficiency disorder in humans involving NK cells[J]. Nature, 1980, 284(5756):553-555.
 
【7】SullivaN JL, Byron KS, Brewster FE, et al. Deficient natural killer cell activity in x-linked lymphoproliferative syndrome[J]. Science, 1980, 210(4469):543-545.
 
【8】Gorelik E, Wiltrout RH, Okumura K, et al. Role of NK cells in the control of metastatic spread and growth of tumor cells in mice[J]. Int J Cancer, 1982, 30(1):107-112.
 
【9】Pross HF, Lotzova E. Role of natural killer cells in cancer[J]. Nat Immun, 1993, 12(4-5):279-292.
 
【10】Strayer DR, Carter WA, Brodsky I. Familial occurrence of breast cancer is associated with reduced natural killer cytotoxicity[J]. Breast Cancer Res Treat, 1986, 7(3):187-192.
 
【11】Morvan MG, Lanier LL. NK cells and cancer:you can teach innate cells new tricks[J]. Nat Rev Cancer, 2016, 16(1):7-19.
 
【12】Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting:integrating immunity's roles in cancer suppression and promotion[J]. Science, 2011, 331(6024):1565-1570.
 
【13】O'Sullivan T, Saddawi-Konefka R, Vermi W, et al. Cancer immunoediting by the innate immune system in the absence of adaptive immunity[J]. J Exp Med, 2012, 209(10):1869-1882.
 
【14】Bezman NA, Kim CC, Sun JC, et al. Molecular definition of the identity and activation of natural killer cells[J]. Nat Immunol, 2012, 13(10):1000-1009.
 
【15】Hudspeth K, Silva-Santos B, Mavilio D. Natural cytotoxicity receptors:broader expression patterns and functions in innate and adaptive immune cells[J]. Front Immunol, 2013, 4:69.
 
【16】Alvarez IB, Pasquinelli V, Jurado JO, et al. Role played by the programmed death-1-programmed death ligand pathway during innate immunity against Mycobacterium tuberculosis[J]. J Infect Dis, 2010, 202(4):524-532.
 
【17】Norris S, Coleman A, Kuri-Cervantes L, et al. PD-1 expression on natural killer cells and CD8(+) T cells during chronic HIV-1 infection[J]. Viral Immunol, 2012, 25(4):329-332.
 
【18】Stojanovic A, Fiegler N, Brunner-Weinzierl M, et al. CTLA-4 is expressed by activated mouse NK cells and inhibits NK cell IFN-gamma production in response to mature dendritic cells[J]. J Immunol, 2014, 192(9):4184-4191.
 
【19】赵沙, 蒋涛, 周彩存. 抗PD-1/PD-L1免疫治疗疗效预测标志物在非小细胞肺癌中的研究进展[J]. 肿瘤,2016, 36(7):823-828.
 
【20】Benson DM Jr, Bakan CE, Mishra A, et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect:a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody[J]. Blood, 2010, 116(13):2286-2294.
 
【21】Boyerinas B, Jochems C, Fantini M, et al. Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells[J]. Cancer Immunol Res, 2015, 3(10):1148-1157.
 
【22】Contardi E, Palmisano GL, Tazzari PL, et al. CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction[J]. Int J Cancer, 2005, 117(4):538-550.
 
【23】Laurent S, Queirolo P, Boero S, et al. The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-alpha production[J]. J Transl Med, 2013, 11:108.
 
【24】Jarahian M, Watzl C, Fournier P, et al. Activation of natural killer cells by newcastle disease virus hemagglutinin-neuraminidase[J]. J Virol, 2009, 83(16):8108-8121.
 
【25】Zamarin D, Holmgaard RB, Subudhi SK, et al. Localized oncolyticvirotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy[J]. Sci Transl Med, 2014, 6(226):226ra32.
 
【26】Romagne F, Andre P, Spee P, et al. Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells[J]. Blood, 2009, 114(13):2667-2677.
 
【27】Vahlne G, Lindholm K, Meier A, et al. In vivo tumor cell rejection induced by NK cell inhibitory receptor blockade:maintained tolerance to normal cells even in the presence of IL-2[J]. Eur J Immunol, 2010, 40(3):813-823.
 
【28】Ndhlovu LC, Lopez-Verges S, Barbour JD, et al. Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity[J]. Blood, 2012, 119(16):3734-3743.
 
【29】Sun H, Sun C, Xiao W. Expression regulation of co-inhibitory molecules on human natural killer cells in response to cytokine stimulations[J]. Cytokine, 2014, 65(1):33-41.
 
【30】Jing W, Gershan JA, WEBER J, et al. Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma[J]. J Immunother Cancer, 2015, 3(1):2.
 
【31】Ngiow SF, Teng MW, Smyth MJ. Prospects for TIM3-Targeted Antitumor Immunotherapy[J]. Cancer Res, 2011, 71(21):6567-6571.
 
【32】Woo SR, Turnis ME, Goldberg MV, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape[J]. Cancer Res, 2012, 72(4):917-927.
 
【33】Melero I, Hirschhorn-Cymerman D, Morales-Kastresana A, et al. Agonist antibodies to TNFR molecules that costimulate T and NK ells[J]. Clin Cancer Res, 2013, 19(5):1044-1053.
 
【34】Asano R, Nakayama M, Kawaguchi H, et al. Construction and humanization of a functional bispecific EGFRx CD16 diabody using a refolding system[J]. FEBS J, 2012, 279(2):223-233.
 
【35】Reusch U, Burkhardt C, Fucek I, et al. A novel tetravalent bispecificTandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells[J]. MAbs, 2014, 6(3):728-739.
 
【36】Kellner C, Bruenke J, Horner H, et al. Heterodimericbispecific antibody-derivatives against CD19 and CD16 induce effective antibody-dependent cellular cytotoxicity against B-lymphoid tumor cells[J]. Cancer Lett, 2011, 303(2):128-139.
 
【37】Bruenke J, Fischer B, Barbin K, et al. A recombinant bispecific single-chain Fv antibody against HLA class Ⅱ and FcgammaR Ⅲ (CD16) triggers effective lysis of lymphoma cells[J]. Br J Haematol, 2004, 125(2):167-179.
 
【38】Kasuya K, Shimazu M, Suzuki M, et al. Bispecific anti-HER2 and CD16 single-chain antibody production prolongs the use of stem cell-like cell transplantation against HER2-overexpressing cancer[J]. Int J Mol Med, 2010, 25(2):209-215.
 
【39】Shahied LS, Tang Y, Alpaugh RK, et al. Bispecificminibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format[J]. J Biol Chem, 2004, 279(52):53907-53914.
 
【40】Singer H, Kellner C, Lanig H, et al. Effective elimination of acute myeloid leukemic cells by recombinant bispecific antibody derivatives directed against CD33 and CD16[J]. J Immunother, 2010, 33(6):599-608.
 
【41】Wiernik A, Foley B, Zhang B, et al. Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16x 33 bispecific killer cell engager and ADAM17 inhibition[J]. Clin Cancer Res, 2013, 19(14):3844-3855.
 
【42】Spear P, Wu MR, Sentman ML et al. NKG2D ligands as therapeutic targets[J]. Cancer Immun, 2013, 13:8.
 
【43】von Sep, Hansen HP, Reiners KS, et al. A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo[J]. Blood, 2006, 107(5):1955-1962.
 
【44】Rothe A, Jachimowicz RD, Borchmann S, et al. The bispecificimmunoligand ULBP2-aCEA redirects natural killer cells to tumor cells and reveals potent anti-tumor activity against colon carcinoma[J]. Int J Cancer, 2014, 134(12):2829-2840.
 
【45】Germain C, Larbouret C, Cesson V, et al. MHC class I-related chain A conjugated to antitumor antibodies can sensitize tumor cells to specific lysis by natural killer cells[J]. Clin Cancer Res, 2005, 11(20):7516-7522.
 
【46】Stamova S, Cartellieri M, Feldmann A, et al. Simultaneous engagement of the activatory receptors NKG2D and CD3 for retargeting of effector cells to CD33-positive malignant cells[J]. Leukemia, 2011, 25(6):1053-1056.
 
【47】Glienke W, Esser R, Priesner C, et al. Advantages and applications of CAR-expressing natural killer cells[J]. Front Pharmaco, 2015, 6:21.
 
【48】Hermanson DL, Kaufman DS. Utilizing chimeric antigen receptors to direct natural killer cell activity[J]. Front Immunol, 2015, 6:195.
 
【49】Chu J, Deng Y, Benson DM, et al. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma[J]. Leukemia, 2014, 28(4):917-927.
 
【50】Li L, Liu LN, Feller S, et al. Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method[J]. Cancer Gene Ther, 2010, 17(3):147-154.
 
【51】Shimasaki N, Fujisaki H, Cho D, et al. A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies[J]. Cytotherapy, 2012, 14(7):830-840.
 
【52】Muller N, Michen S, Tietze S, et al. Engineering NK cells modified with an EGFRvⅢ-specific chimeric antigen receptor to overexpress CXCR4 improves immunotherapy of CXCL12/SDF-1alpha-secreting glioblastoma[J]. J Immunother, 2015, 38(5):197-210.
 
【53】Han J, Chu J, Keung CW, et al. CAR-engineered NK cells targeting wild-type EGFR and EGFRvIII enhance killing of glioblastoma and patient-derived glioblastoma stem cells[J]. Sci Rep, 2015, 5:11483.
 
【54】Boissel L, Betancur-Boissel M, Lu W, et al. Retargeting NK-92 cells by means of CD19-and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity[J]. Oncoimmunology, 2013, 2(10):e26527.
 
相关信息
   标题 相关频次
 临床前癌症模型的研究进展
 16
 PGC-1α与肿瘤代谢关系的研究进展
 10
 乙酰辅酶A合成酶2在肿瘤能量代谢中的研究进展
 10
 抑制肿瘤转移的新策略——靶向肿瘤细胞的外渗过程
 8
 肿瘤血管正常化与肿瘤治疗
 7
 辣椒素抗肿瘤作用研究进展
 5
 瞬时受体通道TRPM8及其对前列腺癌的影响
 5
 转录因子叉头框Q1与肿瘤相关性的研究进展
 5
 K-Ras基因突变型结直肠癌治疗的研究进展
 4
 川芎嗪抑制缺氧诱导的乳腺癌MDA-MB-435S细胞的侵袭及迁移
 4
 晚期糖基化终产物受体异常表达对肿瘤发生和侵袭转移的影响
 4
 CpG寡聚脱氧核苷酸在肿瘤免疫治疗中的应用进展
 3
 嵌合抗原受体修饰的T细胞的临床应用及研究进展
 3
 肿瘤转移新靶点HOTAIR的研究进展
 3
 CRISPR/Cas9基因编辑技术在肿瘤研究及治疗中的应用
 2
 EIF5A2基因在恶性肿瘤中的研究进展
 2
 MS4A基因家族与肿瘤的研究进展
 2
 SEPT 9基因与恶性肿瘤关系的研究进展
 2
 β-胡萝卜素对荷瘤小鼠腹腔巨噬细胞吞噬功能和自然杀伤细胞活性的影响
 2
 125I内放疗联合热疗和化疗治疗中晚期肿瘤的临床观察
 2
 18F-FDG PET/CT在同时性多原发癌中的应用
 2
 1-磷酸鞘氨醇对恶性肿瘤生物学行为调控的研究进展
 2
 3株肺癌细胞中9个肿瘤相关基因的启动子甲基化状态和部分基因表达的相关性(英文)
 2
 AMPK在肿瘤发生发展中的作用机制研究
 2
 Arresten抑制HUVEC细胞增殖和管腔形成的实验研究
 2
 Bcl-2与IP3R相互作用调控肿瘤细胞程序性死亡的研究进展
 2
 CD26/DPPⅣ与肿瘤相关的研究进展
 2
 CDK12与肿瘤相关性的研究进展
 2
 CIK细胞治疗恶性胸腔积液的临床研究
 2
 circRNAs作为生物标志物在肿瘤中的研究进展
 2

  热点专题


关于我们  |   联系我们  |   广告投放  |   《肿瘤》杂志社版权所有 《肿瘤》杂志社   © 中国 上海 2014.3
沪ICP备15036656号-2